Ionis Pharmaceuticals price target raised to $106 from $95 at Barclays

Barclays raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $106 from $95 and keeps an Overweight rating on the shares. The firm boosted its 2034 Tryngolza in severe hypertriglyceridemia estimate to $4B in the U.S. based on “supportive” physician checks. Severe hypertriglyceridemia is the most important near-term opportunity for Ionis and remains underappreciated, the analyst tells investors in a research note.